Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for Juvenile Myelomonocytic Leukemia
NCT00509600Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2004
- Primary completion
- Apr 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etanercept in juvenile myelomonocytic leukemia (JMML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Patient Response at 12 weeks. Started Sep 2004; status: terminated.
02
Drugs
etanercept
03
Conditions
juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT00509600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509600.